Compare Recursion Pharmaceuticals Inc (RXRX) vs Southern Copper Corp (SCCO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Southern Copper Corp — how do they compare? Recursion Pharmaceuticals Inc trades at $4.33 (market cap $2.14B), while Southern Copper Corp trades at $209.14 (market cap $167.74B). The key difference: Southern Copper Corp is far larger — about 78.4× Recursion Pharmaceuticals Inc's market cap, and Southern Copper Corp pays a 2.21% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Recursion Pharmaceuticals Inc for 23 Days and Southern Copper Corp for 61 Days on average.
| RXRX | SCCO | |
|---|---|---|
Market Cap | $2.14B | $167.74B |
Volume | 30,789,535 | 853,110 |
Sector | Health | Basic Materials |
52-Week High | $6.79 | $219.70 |
52-Week Low | $2.84 | $120.02 |
Typical Hold Time | 23 Days | 61 Days |
Enterprise Value | $1.66B | $169.03B |
Dividend Yield | — | 2.21% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $4.255, down 0.35% on the day, with a bullish technical signal from moving averages. The company reported a net loss of $644.76 million in 2025 on $74.26 million revenue, with a negative net income margin of -961.97%. Recent news highlights strategic AI partnerships, including an extended data license with Tempus AI announced September 21, 2026, and pipeline progress presented at the Morgan Stanley Healthcare Conference.
The outlook remains speculative, driven by AI-powered drug discovery potential and partnership milestones, but significant execution risk persists due to heavy losses and high cash burn. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for long-term platform value against near-term financial challenges.
Southern Copper (SCCO) trades at $208.31, up 3.86% over the past day, but remains below the consensus price target of $167.67. The stock shows strong fundamentals with revenue rising to $13.42B in 2025 and net income reaching $4.33B, though valuation ratios like a P/E of 29.81 and P/S of 10.72 appear elevated. Recent earnings beats and a bullish long-term growth outlook from projects like the $10.2B Mexican pipeline contrast with a bearish technical signal and mixed analyst sentiment.
SCCO presents a cautious outlook due to high valuations and bearish technicals, but robust profitability and expansion projects offer growth potential. Key risks include reliance on copper prices and competitive pressures, while institutional activity shows divided interest. Investors should weigh strong cash flows against premium pricing before entry.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Southern Copper Corp
Southern Copper Corp is an integrated producer of copper and other minerals and operates the mining, smelting, and refining facilities in Peru and Mexico. Its production includes copper, molybdenum, zinc, and silver. The company operates through the following segments: Peruvian operations, Mexican open-pit operations, and Mexican underground mining operations. Southern Copper generates the majority of its revenue from the sale of copper and the rest from the sale of non-copper products, such as molybdenum, silver, zinc, lead, and gold. Its geographical segments are The Americas, Europe, and Asia.
Read more on SCCO →
